Literature DB >> 26527439

Unusual Acute Sequelae of α1-Antitrypsin Deficiency: A Myriad of Symptoms With One Common Cure.

Alessandro N Franciosiz1, Cormac McCarthy2, Tomas P Carroll1, Noel G McElvaney1.   

Abstract

Panniculitis associated with α1-antitrypsin deficiency (AATD) is well documented but rare. We report the first case, to our knowledge, of successful induction of clinical remission of AATD-related panniculitis following a single 120-mg/kg dose administration of plasma-purified α1-antitrypsin (AAT). A 23-year-old man with known PiZZ AATD presented to the hospital with a diffusely swollen and tender right upper limb. This was associated with subcutaneous induration, and a discrepancy of 5 cm in upper limb circumference at the mid arm was noted. There was no convincing precipitant for cellulitis or an infectious cause, and inflammatory markers were raised, with a C-reactive protein (CRP) level of 93.9 mg/L and erythrocyte sedimentation rate (ESR) of 71 mm/h. Doppler ultrasonography ruled out DVT. No antimicrobials or antiinflammatory medications were administered during or prior to admission. Biopsy specimens of the right upper limb revealed extensive panniculitis with neutrophils, foamy macrophages, and fat necrosis. A diagnosis of AATD-associated panniculitis was made. Following this, a single IV dose of 120 mg/kg of plasma-purified AAT was administered. By day 7 post AAT infusion, CRP level had normalized to 4.6 mg/L and ESR had dropped to 22 mm/h. Limb circumference discrepancy on day 7 was 1 cm. There was no tenderness to palpation or induration, and a clinical remission of panniculitis was observed. We report the first case, to our knowledge, of clinical remission following a single treatment with IV AAT at a dose of 120 mg/kg. This opens avenues to more timely and effective treatment of the more severe presentations of AAT-associated panniculitis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26527439     DOI: 10.1378/chest.15-0699

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

Review 1.  The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals.

Authors:  Danielle M Dunlea; Laura T Fee; Thomas McEnery; Noel G McElvaney; Emer P Reeves
Journal:  J Inflamm Res       Date:  2018-03-26

2.  Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.

Authors:  Michael E O'Brien; Laura Fee; Niall Browne; Tomás P Carroll; Paula Meleady; Michael Henry; Karen McQuillan; Mark P Murphy; Mark Logan; Cormac McCarthy; Oliver J McElvaney; Emer P Reeves; Noel G McElvaney
Journal:  Thorax       Date:  2020-01-20       Impact factor: 9.139

3.  C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency.

Authors:  Laura T Fee; Debananda Gogoi; Michael E O'Brien; Emer McHugh; Michelle Casey; Ciara Gough; Mark Murphy; Ann M Hopkins; Tomás P Carroll; Noel G McElvaney; Emer P Reeves
Journal:  Biomedicines       Date:  2021-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.